Breaking: FDA Greenlights Profound Medical's TULSA AI Module
- September 26th, 2023
- 798 views
Shares of Profound Medical Corp. (Nasdaq: PROF) surged by more than 10% in after-hours trading after it announced FDA clearance for its Thermal Boost module in conjunction with TULSA-PRO, which allows surgeons to treat various prostate conditions, including cancer and benign prostatic hyperplasia (BPH).
The Thermal Boost module, Profound's first FDA-cleared TULSA AI module, enables surgeons to temporarily increase the ablation target temperature in areas where advanced-stage cancer might be present, improving confidence in effective cancer cell ablation.
$PROF was trading at $10.94 in the extended session, up $1.04 (+10.51%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login